Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants
NCT06157918Phase 1Completed
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SYHA1813 in glioblastoma (GBM), glioma and solid tumor (3 arms), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 1 more. Started Dec 2023; status: completed.
02
Drugs
SYHA1813
03
Conditions
glioblastoma (GBM)gliomasolid tumor
Beyond the preview
Go deeper on NCT06157918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157918.